This inventor holds 2 USPTO granted patents. Top assignee: Codexis, Inc.. Active years: 2018-2019.
Company Filing History:
Years Active: 2018-2019
Title: The Innovative Contributions of Jed Lee Hubbs
Introduction
Jed Lee Hubbs is a notable inventor based in Thalwil, Switzerland. He has made significant contributions to the field of kinase inhibitors, focusing on improving their efficacy and safety. With a total of 2 patents, Hubbs continues to push the boundaries of innovation in pharmaceutical research.
Latest Patents
Hubbs' latest patents include "N-substituted 4-aminoquinazoline derivatives and methods of use." This invention provides kinase inhibitor analogs with enhanced properties, such as improved efficacy, pharmacokinetics, safety, and specificity. In some embodiments, the invention offers lapatinib analogs that deliver therapeutic benefits. Another significant patent is for "Imidazoyl anilide derivatives and methods of use," which also focuses on kinase inhibitor analogs with similar improvements. This patent includes nilotinib analogs that provide therapeutic advantages.
Career Highlights
Jed Lee Hubbs is currently associated with Codexis, Inc., where he applies his expertise in developing innovative pharmaceutical solutions. His work has been instrumental in advancing the field of kinase inhibitors, making a positive impact on therapeutic options available for various diseases.
Collaborations
Hubbs has collaborated with notable colleagues, including Gjalt W Huisman and Xiyun Zhang. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic agents.
Conclusion
Jed Lee Hubbs is a prominent inventor whose work in kinase inhibitors has led to significant advancements in pharmaceutical research. His contributions continue to shape the future of therapeutic innovations.